Processing

Please wait...

Settings

Settings

Goto Application

1. WO2012065044 - TREATING BLADDER TUMOR CELLS USING FIBRONECTIN ATTACHMENT PROTEIN AS A TARGET

Publication Number WO/2012/065044
Publication Date 18.05.2012
International Application No. PCT/US2011/060339
International Filing Date 11.11.2011
IPC
A61K 39/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
C07K 16/00 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
CPC
A61K 2039/505
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
505comprising antibodies
A61K 38/164
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
164from bacteria
A61K 47/64
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51the non-active ingredient being a modifying agent
62the modifying agent being a protein, peptide or polyamino acid
64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
A61K 47/6835
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51the non-active ingredient being a modifying agent
68the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
6835the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
A61K 47/6881
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51the non-active ingredient being a modifying agent
68the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
6835the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
6881Cluster-antibody conjugates, i.e. the modifying agent consists of a plurality of antibodies covalently linked to each other or of different antigen-binding fragments covalently linked to each other
A61K 47/6913
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
69the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
6905the form being a colloid or an emulsion
6911the form being a liposome
6913the liposome being modified on its surface by an antibody
Applicants
  • PURDUE RESEARCH FOUNDATION [US]/[US] (AllExceptUS)
  • AGUILAR, Ruben, Claudio [AR]/[US] (UsOnly)
  • RATLIFF, Timothy [US]/[US] (UsOnly)
  • THOMPSON, David [US]/[US] (UsOnly)
  • CRIST, Scott [US]/[US] (UsOnly)
Inventors
  • AGUILAR, Ruben, Claudio
  • RATLIFF, Timothy
  • THOMPSON, David
  • CRIST, Scott
Agents
  • ADDISON, Bradford, G.
Priority Data
61/412,97312.11.2010US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) TREATING BLADDER TUMOR CELLS USING FIBRONECTIN ATTACHMENT PROTEIN AS A TARGET
(FR) TRAITEMENT DE CELLULES TUMORALES DE LA VESSIE À L'AIDE DE LA PROTÉINE DE LIAISON À LA FIBRONECTINE COMME CIBLE
Abstract
(EN)
Composition and methods are disclosed for utilizing micro-aggregation of FAP- containing complexes to promote their fast internalization. This approach allows the uptake of cytotoxic cargo coupled to either FAP-Antibodies or FAP-liposome complexes by tumor bladder cells. Importantly, this approach is efficient even under serum- free conditions such as the ones found in the lumen of the bladder.
(FR)
L'invention concerne des compositions et des procédés pour l'utilisation de la micro-agrégation de complexes contenant FAP pour promouvoir leur rapide internalisation. Cette approche permet la capture d'une protéine cargo cytotoxique couplée soit à des anticorps anti-FAP ou à complexes liposome-FAP, par des cellules tumorales de vessie. De manière importante, cette approche est efficace même dans des conditions exemptes de sérum, telles que celles que l'on trouve dans la lumière de la vessie.
Also published as
Latest bibliographic data on file with the International Bureau